| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 6,493 | 6,691 | 6,973 | 7,260 | 7,622 | 8,164 | 7,869 | 7,805 | 7,050 | 6,319 | 6,845 | 6,727 | 7,014 | 7,339 | 7,198 | 7,850 | 7,326 | 8,472 | 8,150 | 8,159 | 8,180 | 7,640 | 9,019 | 9,124 | 8,575 | 9,822 | 9,780 | 10,247 | 9,500 | 10,646 | 10,894 | 11,274 | 11,099 | 11,990 | 12,297 | 12,407 | 12,419 | 13,057 | 13,618 | 13,903 | 13,429 | 14,251 | 14,875 | 16,048 |
| Expenses | 5,318 | 5,679 | 5,000 | 4,877 | 5,382 | 5,335 | 5,092 | 5,472 | 5,590 | 6,064 | 5,275 | 5,200 | 5,294 | 5,618 | 6,621 | 5,587 | 6,147 | 6,379 | 6,334 | 6,314 | 7,083 | 9,375 | 6,360 | 6,431 | 7,147 | 7,529 | 6,996 | 7,257 | 11,042 | 7,877 | 7,996 | 8,237 | 8,300 | 8,932 | 9,013 | 8,974 | 9,049 | 9,045 | 9,352 | 9,983 | 9,604 | 10,368 | 9,951 | 11,062 |
| EBITDA | 1,175 | 1,012 | 1,973 | 2,383 | 2,240 | 2,829 | 2,776 | 2,333 | 1,460 | 255 | 1,570 | 1,528 | 1,720 | 1,721 | 577 | 2,263 | 1,179 | 2,094 | 1,816 | 1,845 | 1,098 | -1,736 | 2,659 | 2,693 | 1,427 | 2,293 | 2,784 | 2,990 | -1,542 | 2,769 | 2,899 | 3,037 | 2,799 | 3,058 | 3,284 | 3,433 | 3,370 | 4,012 | 4,266 | 3,920 | 3,824 | 3,883 | 4,924 | 4,986 |
| Operating Profit % | 13 % | 13 % | 27 % | 31 % | 27 % | 33 % | 34 % | 29 % | 18 % | 2 % | 20 % | 21 % | 21 % | 21 % | 3 % | 27 % | 13 % | 23 % | 20 % | 21 % | 12 % | -25 % | 25 % | 27 % | 16 % | 22 % | 27 % | 26 % | -18 % | 26 % | 26 % | 26 % | 23 % | 24 % | 25 % | 26 % | 23 % | 28 % | 29 % | 26 % | 25 % | 25 % | 31 % | 28 % |
| Depreciation | 462 | 240 | 258 | 251 | 288 | 316 | 304 | 307 | 338 | 347 | 359 | 339 | 455 | 402 | 427 | 471 | 454 | 457 | 473 | 547 | 575 | 496 | 499 | 532 | 554 | 503 | 530 | 554 | 557 | 588 | 610 | 660 | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 |
| Interest | 135 | 135 | 158 | 128 | 103 | 135 | 54 | 167 | 45 | 109 | 157 | 95 | 155 | 131 | 130 | 145 | 150 | 104 | 84 | 63 | 52 | 52 | 33 | 26 | 30 | 35 | 36 | 19 | 37 | 14 | 19 | 46 | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 |
| Profit Before Tax | 591 | 872 | 1,572 | 2,040 | 2,087 | 2,628 | 2,930 | 2,102 | 1,389 | -159 | 1,114 | 1,148 | 1,376 | 1,274 | 112 | 1,730 | 694 | 1,647 | 1,433 | 1,351 | 577 | -2,184 | 2,206 | 2,163 | 903 | 1,804 | 2,287 | 2,466 | -2,076 | 2,285 | 2,412 | 2,472 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 |
| Tax | -596 | 115 | 272 | 100 | 424 | 360 | 458 | 380 | 3 | 164 | 113 | 792 | -187 | 88 | 272 | 269 | -26 | 151 | 270 | 332 | 85 | 242 | 263 | 250 | 61 | 400 | 200 | 340 | 152 | 191 | 157 | 291 | 257 | 476 | 406 | 440 | 157 | 563 | 561 | 563 | 1,100 | 880 | 1,043 | 846 |
| Net Profit | 1,186 | 757 | 1,299 | 1,940 | 1,663 | 2,268 | 2,471 | 1,722 | 1,386 | -323 | 1,002 | 356 | 1,563 | 1,186 | -160 | 1,461 | 721 | 1,497 | 1,163 | 1,019 | 493 | -2,426 | 1,943 | 1,913 | 842 | 1,404 | 2,086 | 2,126 | -2,227 | 2,093 | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 |
| EPS in ₹ | 3.70 | 2.30 | 4.30 | 6.40 | 5.90 | 8.50 | 9.30 | 6.10 | 5.20 | -1.77 | 3.80 | 1.34 | 5.60 | 4.41 | -1.12 | 5.18 | 2.65 | 5.78 | 4.43 | 3.81 | 1.67 | -6.90 | 7.56 | 7.72 | 3.70 | 6.00 | 8.50 | 8.60 | -9.50 | 8.60 | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 |
Sun Pharmaceutical
Sun Pharmaceutical
1,862.40
+37.60
(2.06%)
Market Cap
4,46,852.14 Cr
PE Ratio
39.96
Volume
14,95,462.00
Day High - Low
1,867.50 - 1,829.70
52W High-Low
1,885.80 - 1,548.00
There are 1 new updates from the company19 hrs ago
View
Key Fundamentals
Market Cap
4,46,852.14 Cr
EPS
45.60
PE Ratio
39.96
PB Ratio
5.63
Book Value
324.34
EBITDA
17,236.70
Dividend Yield
0.88 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
15.15
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from31 analysts
Actual
Company News
View All News
Sun Pharmaceutical received reclassification requests on 14 May 2026 from three Promoter Group members holding 4,31,75,371 shares (1.80%) seeking Public category status.
Sun Pharmaceutical Industries will announce Q4 results for the quarter ended 31 March 2026 on 22 May 2026, followed by an earnings conference call at 06.30 pm IST.
Sun Pharmaceutical's Board approves Dr. Andreas Busch as Independent Director for five consecutive years from 12 May 2026, pending shareholder approval.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,862.40 | #1 4,46,852.14 | #6 39.96 | #1 54,729.00 | #6 9.71 | #1 10,980 | #4 16.07 | 58.45 | |
6,913.50 | 1,83,531.70 | 72.74 | 9,712.00 | 18.67 | 2,191 | -1.02 | 72.69 | |
4,380.90 | 1,48,269.56 | 63.98 | 11,539.40 | 6.99 | 1,911 | 26.24 | 52.52 | |
1,418.60 | 1,14,591.77 | 27.76 | 27,711.70 | -2.46 | 3,783 | -55.32 | 56.75 | |
1,301.60 | 1,08,637.14 | 25.40 | 33,593.30 | -0.44 | 3,998 | -86.05 | 47.13 | |
2,259.40 | 1,03,264.34 | 18.91 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 38.38 | |
2,450.40 | 1,01,153.75 | 55.11 | 12,744.20 | 20.90 | 2,007 | 7.65 | 67.26 | |
994.35 | 1,00,054.88 | #1 18.80 | 23,511.00 | 18.55 | 4,615 | -0.32 | 55.29 | |
1,507.70 | 87,567.46 | 24.96 | 32,345.60 | 9.43 | 3,484 | 7.59 | 71.98 | |
1,302.80 | 70,332.52 | 77.65 | 6,812.90 | #1 21.03 | 884 | 21.18 | 76.81 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
9.71 %
Net Income Growth
13.80 %
Cash Flow Change
15.96 %
ROE
5.43 %
ROCE
14.46 %
EBITDA Margin (Avg.)
9.26 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,500 | 92,101 |
| Fixed Assets | 12,683 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 |
| Current Assets | 29,122 | 29,941 | 32,954 | 31,636 | 31,069 | 31,654 | 30,442 | 34,865 | 39,862 | 43,433 | 52,594 |
| Capital Work in Progress | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 |
| Investments | 2,117 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 |
| Other Assets | 32,189 | 35,653 | 39,742 | 36,056 | 33,544 | 34,042 | 34,935 | 33,007 | 36,881 | 41,872 | 44,517 |
| Total Equity & Liabilities | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,500 | 92,101 |
| Current Liabilities | 16,353 | 13,144 | 17,887 | 19,864 | 17,340 | 15,706 | 16,146 | 17,208 | 19,906 | 16,984 | 18,194 |
| Non Current Liabilities | 4,186 | 5,319 | 3,093 | 2,454 | 2,632 | 3,421 | 2,041 | 1,533 | 1,522 | 1,390 | 1,420 |
| Total Equity | 28,489 | 37,068 | 40,431 | 42,198 | 44,723 | 49,125 | 49,480 | 51,066 | 59,316 | 67,126 | 72,486 |
| Reserve & Surplus | 25,383 | 32,741 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 |
| Share Capital | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 116 | 4,662 | 983 |
| Investing Activities | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 | -5,183 |
| Operating Activities | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 |
| Financing Activities | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,981 | -5,194 | 2,376 | -6,710 | -7,906 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.79 % | 0.00 % | 17.72 % | 17.23 % | 18.02 % | 18.05 % | 17.96 % | 17.26 % | 16.55 % | 16.12 % | 15.93 % |
| DIIs | 21.59 % | 21.93 % | 21.67 % | 20.94 % | 19.94 % | 19.57 % | 18.60 % | 19.14 % | 19.24 % | 19.75 % | 19.67 % | 17.97 % | 18.83 % | 19.28 % | 18.61 % | 18.55 % | 18.70 % | 19.50 % | 20.24 % | 20.82 % | 21.11 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.34 % | 7.21 % | 6.79 % | 6.68 % | 6.49 % | 6.31 % | 5.91 % | 5.76 % | 5.70 % | 5.65 % | 5.56 % | 5.41 % | 5.44 % | 5.57 % | 5.43 % | 5.47 % | 5.42 % | 5.35 % | 5.53 % | 5.40 % | 5.30 % |
| Others | 16.60 % | 16.38 % | 17.05 % | 17.90 % | 19.09 % | 19.64 % | 21.01 % | 20.63 % | 20.58 % | 20.12 % | 3.51 % | 22.13 % | 3.53 % | 3.44 % | 3.46 % | 3.46 % | 3.45 % | 3.42 % | 3.20 % | 3.18 % | 3.18 % |
| No of Share Holders | 0 | 7,09,045 | 7,57,366 | 6,75,908 | 6,80,800 | 6,62,384 | 6,47,167 | 6,43,512 | 6,25,252 | 6,24,561 | 6,16,588 | 6,12,626 | 6,31,392 | 6,73,217 | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3.5 | 2 | 2.75 | 4 | 7.5 | 10 | 11.5 | 13.5 | 16 | 0.00 |
| Dividend Yield (%) | 0.71 | 0.42 | 0.78 | 0.67 | 0.82 | 1.01 | 0.71 | 0.78 | 0.91 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 May 2026 |  Quarterly Result Announcement | NA | 22 May 2026 | 1,847.90 | 1,824.40 |
| 10 Feb 2021 |  Dividend | ₹ 5.50 /share | 09 Feb 2021 | 564.35 | 623.60 |
| 25 Aug 2021 | Dividend | ₹ 2.00 /share | 23 Aug 2021 | 703.80 | 771.35 |
| 10 Feb 2022 | Dividend | ₹ 7.00 /share | 09 Feb 2022 | 827.35 | 886.45 |
| 22 Aug 2022 | Dividend | ₹ 3.00 /share | 19 Aug 2022 | 903.90 | 901.35 |
| 08 Feb 2023 | Dividend | ₹ 7.50 /share | 08 Feb 2023 | 1,050.90 | 1,005.65 |
| 28 Jul 2023 | Dividend | ₹ 4.00 /share | 28 Jul 2023 | 945.00 | 1,134.95 |
| 09 Feb 2024 | Dividend | ₹ 8.50 /share | 09 Feb 2024 | 1,371.60 | 1,500.25 |
| 12 Jul 2024 | Dividend | ₹ 5.00 /share | 12 Jul 2024 | 1,541.15 | 1,583.25 |
| 05 Aug 2024 |  Annual General Meeting | NA | 05 Aug 2024 | 1,520.65 | 1,731.65 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 1,916.85 | 1,860.40 |
| 21 Jan 2025 |  Extraordinary General Meeting | NA | 21 Jan 2025 | 1,806.20 | 1,778.25 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 1,756.85 | 1,739.10 |
| 06 Feb 2025 | Dividend | ₹ 10.50 /share | 06 Feb 2025 | 1,739.10 | 1,753.40 |
| 22 May 2025 | Quarterly Result Announcement | NA | 22 May 2025 | 1,744.85 | 1,731.60 |
| 07 Jul 2025 | Dividend | ₹ 5.50 /share | 07 Jul 2025 | 1,731.60 | 1,676.65 |
| 31 Jul 2025 | Annual General Meeting | NA | 31 Jul 2025 | 1,731.60 | 1,734.95 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 1,663.15 | 1,734.95 |
| 05 Nov 2025 | Quarterly Result Announcement | NA | 05 Nov 2025 | 1,668.50 | 1,690.00 |
| 31 Jan 2026 | Quarterly Result Announcement | NA | 31 Jan 2026 | 1,673.55 | 1,595.00 |
| 05 Feb 2026 | Dividend | ₹ 11.00 /share | 05 Feb 2026 | 1,595.00 | 1,704.00 |
Announcements
Intimation For Receipt Of Requests For Reclassification Of Shareholder Category
1 hr ago
1 hr agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation19 hrs ago
19 hrs agoAnnouncement under Regulation 30 (LODR)-Change in Directorate1 day ago
1 day agoBoard Meeting Intimation for Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Final Dividend For FY 2025-262 days ago
2 days agoCompletion And Result Of Postal Ballot Dated 07 April 20265 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Credit Rating6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript8 days ago
8 days agoInvestor Call Audio RecordingApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Investor PresentationApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-AcquisitionApr 27, 2026
Apr 27, 2026Incorporation Of A Subsidiary CompanyApr 24, 2026
Apr 24, 2026Completion And Results Of Postal Ballot Dated 17 March 2026Apr 17, 2026
Apr 17, 2026Rumour verification - Regulation 30(11)Apr 10, 2026
Apr 10, 2026Clarification sought from Sun Pharmaceutical Industries LtdApr 10, 2026
Apr 10, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 08, 2026
Apr 08, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotApr 07, 2026
Apr 07, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateApr 04, 2026
Apr 04, 2026Updates On Fibromun And NidlegyMar 28, 2026
Mar 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 27, 2026
Mar 27, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 21, 2026
Mar 21, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 18, 2026
Mar 18, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 17, 2026
Mar 17, 2026Shareholder Satisfaction Survey On RTA ServicesMar 17, 2026
Mar 17, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 16, 2026
Mar 16, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2026
Feb 03, 2026Sustainability Report For The Financial Year 2024-25Feb 02, 2026
Feb 02, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2026
Feb 01, 2026Q3FY26 Earnings Call Audio RecordingJan 31, 2026
Jan 31, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateJan 31, 2026
Jan 31, 2026Corporate Action-Board approves DividendJan 31, 2026
Jan 31, 2026Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025Jan 31, 2026
Jan 31, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2026
Jan 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 21, 2026
Jan 21, 2026Intimation Of The Record Date For The Purpose Of The Interim Dividend For FY 2025-26 Is 05 February 2026Jan 20, 2026
Jan 20, 2026Board Meeting Intimation for Approval Of Financial Results For The Quarter And Nine Months Ended 31 December 2025 And The Interim Dividend For FY 2025-26Jan 20, 2026
Jan 20, 2026Rumour verification - Regulation 30(11)Jan 19, 2026
Jan 19, 2026Clarification sought from Sun Pharmaceutical Industries LtdJan 19, 2026
Jan 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 15, 2026
Jan 15, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 14, 2026
Jan 14, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2026
Jan 09, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Investor PresentationDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 23, 2025
Dec 23, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Determines Baska Facility Inspection Classification As OAIDec 18, 2025
Dec 18, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.45
ATR(14)
Less Volatile 45.32
STOCH(9,6)
Overbought 82.82
STOCH RSI(14)
Overbought 85.23
MACD(12,26)
Bullish 11.39
ADX(14)
Weak Trend 24.47
UO(9)
Bearish 54.41
ROC(12)
Uptrend And Accelerating 12.61
WillR(14)
Neutral -22.41
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun...more
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
